Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, Daikos GL, Wang M, Torre-Cisneros J, Singer G, Titov I, Gumenchuk I, Zhao Y, Jiménez-Rodríguez RM, Liang L, Chen G, Pyptiuk O, Aksoy F, Rogers H, Wible M, Arhin FF, Luckey A, Leaney JL, Pypstra R, Chow JW; COMBACTE-CARE consortium REVISIT study group.
Carmeli Y, et al. Among authors: jimenez rodriguez rm.
Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00499-7. doi: 10.1016/S1473-3099(24)00499-7. Online ahead of print.
Lancet Infect Dis. 2024.
PMID: 39389071